Clinicopathological predictors for low risk recurrence distinguished by 21-gene recurrence score in estrogen receptor-positive invasive breast cancer patients

被引：0
|
作者：
Tsuchida, Y. [1 ]
Hayashi, N. [1 ]
Omata, F. [1 ]
Yamauchi, H. [1 ]
机构：
[1] St Lukes Int Hosp, Chuo Ku, Tokyo, Japan
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P2-05-36
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-05-36
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
    Wu Jiayi
    Fang Yan
    Lin Lin
    Fei Xiaochun
    Gao Weiqi
    Zhu Siji
    Zong Yu
    Chen Xiaosong
    Huang Ou
    He Jianrong
    Zhu Li
    Chen Weiguo
    Li Yafen
    Shen Kunwei
    ONCOTARGET, 2017, 8 (24) : 38706 - 38716
  • [32] The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
    Lee, Moo Hyun
    Han, Wonshik
    Lee, Jeong Eon
    Kim, Ku Sang
    Park, Heeseung
    Kim, Jongjin
    Bae, Soo Youn
    Shin, Hyun Joo
    Lee, Jong Won
    Lee, Eun Sook
    CANCER RESEARCH AND TREATMENT, 2015, 47 (02): : 208 - 214
  • [33] Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer
    Oratz, Ruth
    Kim, Benjamin
    Chao, Calvin
    Skrzypczak, Stanley
    Ory, Caron
    Bugarini, Roberto
    Broder, Michael
    JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (02) : 94 - +
  • [34] Predictive value of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer
    Lu, Kai
    Li, Hui
    Wu, Zhaoshu
    Liu, Dong
    Ye, Hongling
    Xu, Liang
    Liu, Yanwen
    JOURNAL OF BUON, 2018, 23 (05): : 1297 - 1301
  • [35] Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer
    Takayuki Ueno
    Norikazu Masuda
    Takeharu Yamanaka
    Shigehira Saji
    Katsumasa Kuroi
    Nobuaki Sato
    Hiroyuki Takei
    Yutaka Yamamoto
    Shinji Ohno
    Hiroko Yamashita
    Kazufumi Hisamatsu
    Kenjiro Aogi
    Hiroji Iwata
    Hironobu Sasano
    Masakazu Toi
    International Journal of Clinical Oncology, 2014, 19 : 607 - 613
  • [36] Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
    David D. Yang
    Daniela L. Buscariollo
    Angel M. Cronin
    Shicheng Weng
    Melissa E. Hughes
    Richard J. Bleicher
    Adam L. Cohen
    Sara H. Javid
    Stephen B. Edge
    Beverly Moy
    Joyce C. Niland
    Antonio C. Wolff
    Michael J. Hassett
    Rinaa S. Punglia
    Radiation Oncology, 15
  • [37] Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
    Yang, David D.
    Buscariollo, Daniela L.
    Cronin, Angel M.
    Weng, Shicheng
    Hughes, Melissa E.
    Bleicher, Richard J.
    Cohen, Adam L.
    Javid, Sara H.
    Edge, Stephen B.
    Moy, Beverly
    Niland, Joyce C.
    Wolff, Antonio C.
    Hassett, Michael J.
    Punglia, Rinaa S.
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [38] Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer
    Zhu, Lizhe
    Ma, Nan
    Wang, Bin
    Zhou, Can
    Yan, Yu
    Wang, Ke
    He, Jianjun
    Ren, Yu
    ONCOLOGY LETTERS, 2019, 17 (06) : 5469 - 5480
  • [39] Association of human epidermal growth factor receptor 2 expression with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
    Ma, Sung Jun
    Gill, Jasmin
    Yendamuri, Keerti
    Yao, Song
    Oladeru, Oluwadamilola Temilade
    Singh, Anurag K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Association of 21-gene recurrence score and locoregional recurrence in early breast cancer patients
    Zeng, Yufei
    Gao, Weiqi
    Chen, Xiaosong
    Shen, Kunwei
    CANCER BIOMARKERS, 2022, 35 (01) : 111 - 118
12345